Ovid Therapeutics Inc - ESG Rating & Company Profile powered by AI
This webpage of Ovid Therapeutics Inc is assembled by All Street Sevva using advanced machine learning. Complete ESG analysis of Ovid Therapeutics Inc can be reached by logging in. The ESG score covers seventeen UN SDGs including: 'Zero Hunger', 'Decent Work & Economic Growth' and 'Peace, Justice & Strong Institutions'.
Ovid Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 5.3, social score of 1.6 and governance score of 4.0.
3.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1132 | Taro Pharmaceutical Industries Ltd | 3.7 | Medium |
| 1132 | Traphaco JSC | 3.7 | Medium |
| 1144 | Ovid Therapeutics Inc | 3.6 | Medium |
| 1144 | CellSeed Inc | 3.6 | Medium |
| 1144 | Cellectar Biosciences Inc | 3.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Ovid Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Ovid Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Ovid Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Ovid Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Ovid Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Ovid Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Ovid Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Ovid Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Ovid Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Ovid Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Ovid Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Ovid Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Ovid Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Ovid Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Ovid Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Ovid Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Ovid Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Ovid Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.